Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alveolar bone resorption07.09.05.010; 15.02.03.0130.000035%-
Graft versus host disease in gastrointestinal tract07.11.01.027; 10.02.01.059; 12.02.09.0280.000070%-
Poor feeding infant14.03.02.022; 18.04.06.0060.000035%-
Gastrointestinal wall thickening07.01.06.0320.000052%-
Macular detachment06.09.03.0200.000035%-
Unmasking of previously unidentified disease08.01.03.0800.000140%-
Steatohepatitis09.01.07.024; 14.08.04.0200.000035%-
Gluten sensitivity07.17.01.009; 10.01.01.031; 14.02.01.0080.000035%-
Pharyngeal paraesthesia17.02.06.035; 22.04.05.0180.000035%-
Intensive care unit acquired weakness15.05.05.012; 17.09.01.0040.000105%-
Neuromyelitis optica spectrum disorder06.04.08.003; 10.04.10.015; 17.16.02.0050.000035%-
Acute macular neuroretinopathy06.10.02.008; 17.17.01.0260.000035%-
Adrenal adenoma05.01.04.009; 16.37.03.0020.000035%-
Anaplastic large cell lymphoma T- and null-cell types stage II01.11.02.003; 16.17.02.0030.000035%-
Angioimmunoblastic T-cell lymphoma stage IV01.11.05.002; 16.17.05.0020.000035%-
Aortic valve disease mixed02.07.03.0110.000035%-
Benign uterine neoplasm16.04.02.004; 21.07.02.0140.000070%-
Brief psychotic disorder with marked stressors19.03.05.0030.000035%-
Cardiac dysfunction02.11.01.0040.000035%-
Castleman's disease01.13.02.005; 16.21.02.0050.000035%-
Central serous chorioretinopathy06.10.02.0090.000052%-
Cerebral venous sinus thrombosis17.08.03.006; 24.01.04.0210.000105%-
Chorioretinal folds06.09.01.0130.000087%-
Cold type haemolytic anaemia01.06.01.007; 10.04.01.0110.000035%-
Cutaneous T-cell lymphoma stage I01.11.03.005; 16.17.03.005; 23.07.04.0320.000052%-
Cutaneous T-cell lymphoma stage IV01.11.03.008; 16.17.03.008; 23.07.04.0350.000035%-
Defaecation disorder07.02.03.0080.000035%-
Dermatopathic lymphadenopathy01.09.01.030; 23.07.04.0380.000035%-
Differentiation syndrome08.01.07.016; 12.03.01.063; 16.32.03.037; 22.02.01.0360.000052%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.000479%-
The 33th Page    First    Pre   33 34 35 36    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene